All News

Article

Turning the Corner on CV Risk in Rheumatoid Arthritis

Richard Conway, MBBChBAO, PhD Jun 03, 2021

Cardiovascular (CV) disease remains the leading cause of mortality in rheumatoid arthritis (RA). A number of studies progressed our knowledge in the session Rheumatoid arthritis - comorbidity and clinical aspects – I on Thursday at EULAR 2021.

News Feature: EULAR 2021 – Day 1 Report #EULAR2021 https://t.co/igpQYMkf9l https://t.co/qESsN3meJe

https://bit.ly/3pjENT1

Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson Dr. Yusof interviews Dr. Robinson about abstract OP0013, presented at the virtual #EULAR2021 meeting. https://t.co/IPe6lMM7NQ

https://bit.ly/3g8wMfj

How common is RA ILD? @RheumNow #EULAR2021 @eular_org

RA ILD is NOT a needle in a haystack! Older age& makes & COPD is a risk MUC5B gene SNIP are risks NOT ACPA. 7-10% will have relevant RA ILD. Are you ready to identity & treat it? @RheumNow #EULAR2021 BI RA ILD symposium @eular_org https://t.co/4mS6Jejjqk

Glad to present my own work in the irAE session #EULAR2021 PET/CT can help show us that PMR irAEs are a distinct phenomenon, not just generalised immune activation... and if we can understand PMR irAEs maybe we can understand a bit about classical PMR as well! OP0194 @RheumNow https://t.co/d4yjExjES3

Leave my MTX alone says pt & #rheumatologist if pt has chronic ILD. Acute pneumonia from MTX is NOT chronic ILD in RA @RheumNow @eular_org #EULAR2021 #BoehringerIngelheim RA ILD silent killer symposium https://t.co/IQTINuUpVq

#POS0196 1 year results of the SELECT-PsA 2 study: Inadequate responders to ≥1bDMARD subjected to #upadacitinib maintained efficacy throughout week 56 (74% of pts completed 1-year) #EULAR2021 @RheumNow https://t.co/xpqhzgeI6q

Complements that are low in #SLE pregnancy have POORER fetal outcomes. What happens to C3 & C4 in pregnancy? They should ⬆️ by 28% C3, 11% C4 in 1st Trimester ⁦@RheumNow⁩ #EULAR2021 POS0103. So order C3&C4 early in pregnancy in SLE & follow! https://t.co/FpHHj74e43

Great talks on comorbidities in RA at #EULAR2021 today. What do we struggle most with in RA management? @RheumNow

Can well controlled SLE pt taper #Belimumab? Maybe. Single site w 48 pts & over 2 yrs 44% could taper esp if on #plaquenil. This may change my practice but will follow pts closely POS0107 ⁦@RheumNow⁩ #EULAR2021 ⁦@eular_org⁩ https://t.co/8WCrt11ubV

Check out our psoriatic arthritis coverage from #EULAR2021. Head to RheumNow for full EULAR coverage. https://t.co/NzB2e2Vfwb

https://bit.ly/3vQajub

RheumNow’s expanded coverage of the #EULAR2021 meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

From bedside to bench–unexpected results of clinical studies that changed our understanding of the disease #EULAR2021. “SpA” talk by Prof. Désirée van der Heijde. Inhibition of TNF, IL-17, IL-23, IL-6, IL-1, co-stimulation and B cell depletion in immunology perspective 👏 /TK https://t.co/JFr3VC8sXY

Novel MOA Rx SLE skin #OP0132 Iberdomide: high affinity cereblon ligand ➡️proteasomal degradation of Ikaros&Aiolos - works for SCLE & CCLE - works early 4 wks, cont improves at 24 wks - high PCB resp wk 24, CLASI nonsig - dose dept AE's ⬇️WBC, infx, rash #EULAR2021 @rheumnow https://t.co/wYLdAZLvJq

What about musculoskeletal #pain in PsO patients? Results of a nationwide Danish survey #POS0149 that shed light into unadressed reduced quality of life and risk to move towards #PsA #EULAR2021 @RheumNow https://t.co/JQnHSvtpHm

“When patients present with LN, they already lost alot of nephrons!” - Prof F Houussiau on the importance of early aggressive Rx for LN #EULAR2021 @rheumnow

Patient with SLE says I am flaring BUT you say No! Just like in RA, there often is poor QoL. POS0101 Despite response to Rx SF36 shows less QoL vs pop’n. Need to look at what can be improved beyond active SLE #EULAR ⁦@RheumNow⁩ ⁦@eular_org⁩ https://t.co/C17FRTBsUq

RA ILD will kill pts esp UIP pattern and extent & presence of honeycombing on HRCT. Think about it esp if older pt #EULAR2021 #BoehringerIngelheim symposium @RheumNow @eular_org https://t.co/be2Z7KMqpg

OPO132: Dr. Werth presents Iberdomide targeting cereblon ligand on SLE skin. Iberdomide 0.45 mg QD showed improvement vs PBO for SCLE & CCLE, not seen for ACLE. Interesting new target, affects B cell and type 1 IFN pathways @Rheumnow #Eular2021 https://t.co/nuDM7h59MB

Topics

All News

Turning the Corner on CV Risk in Rheumatoid Arthritis

Do you get our email newsletter?